Youre giving your skin an upgrade
4o) exhibited a 4.7-fold increase following proflavine administration
Kasemkijwattana, C., et al., Use of Growth Factors to Improve Muscle Healing After Strain Injury
Research findings reveal substantially elevated gastrointestinal risks demonstrating: Pancreatitis Risk : Patients using GLP-1 agonists showed a 9.09-fold increased risk (adjusted hazard ratio) for developing pancreatitis compared to those using alternative weight loss medications Gastroparesis Development : The study revealed a 3.67-fold increased risk for gastroparesis, often occurring secondary to pancreatic inflammation Bowel Obstruction : A 4.22-fold increased risk for intestinal blockages was documented, frequently accompanying severe gastroparesis cases FDA Adverse Event Reports : Analysis of the FDAs FAERS database through 2024 shows over 900 reported cases of pancreatitis specifically linked to semaglutide use Post-Marketing Surveillance : Real-world data from 2023-2024 indicates that serious gastrointestinal events occur more frequently than initially reported in clinical trials When pancreatitis develops, the inflamed pancreas releases numerous enzymes, toxic substances, and vasoactive compounds including inflammatory cytokines that can damage the autonomic nervous system controlling gastric function
But besides simply not pooping regularly, constipation from semaglutide and other GLP-1 medications can present as: Fewer than three bowel movements per week Hard, dry, or lumpy stools Straining during bowel movements Feeling of incomplete evacuation Abdominal discomfort or bloating Hard stool followed by watery loose stool Its important to distinguish between occasional constipation (which is common) and chronic constipation , which may require assistance to address the cause
